A Phase 3, Randomized, Active-Controlled, Double Blind Study Comparing Upadacitinib to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs)
Phase of Trial: Phase III
Latest Information Update: 05 Apr 2018
At a glance
- Drugs Upadacitinib (Primary) ; Abatacept
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms SELECT-CHOICE
- Sponsors AbbVie
- 30 Mar 2018 Planned End Date changed from 29 Mar 2021 to 30 Mar 2021.
- 31 Oct 2017 Planned End Date changed from 26 Mar 2021 to 29 Mar 2021.
- 31 Jul 2017 Planned End Date changed from 29 Apr 2021 to 26 Mar 2021.